TABLE 3.
RWJ-270201 and oseltamivir protect mice against lethal infection with H5N1 and H9N2 influenza viruses
| Virus | Treatmenta | Dosage (mg/kg/day) | No. of survivors/total | Survival rate (%) | Mean survival ± SE (no. of days)b | P valuec |
|---|---|---|---|---|---|---|
| A/HK/156/97 (H5N1) | RWJ-270201 | 0.01 | 3/10 | 30.0 | 9.9 ± 1.4 | 0.014 |
| 0.1 | 7/10 | 70.0 | 13.4 ± 1.3 | 0.0002 | ||
| 1.0 | 9/10 | 90.0 | 15.0 ± 1.0 | 0.00003 | ||
| 1.0 | 9/9 | 100.0 | 16.0 ± 0 | <0.0001 | ||
| Oseltamivir | 0.01 | 2/6 | 33.3 | 11.3 ± 1.5 | 0.003 | |
| 0.1 | 6/6 | 100.0 | 16.0 ± 0 | 0.0001 | ||
| 1.0 | 5/5 | 100.0 | 16.0 ± 0 | 0.0001 | ||
| PBS (control) | 0 | 0/11 | 0 | 6.3 ± 0.4 | ||
| A/quail/HK/G1/97 (H9N2) | RWJ-270201 | 0.01 | 3/12 | 25.0 | 9.3 ± 1.2 | 0.684 |
| 0.1 | 4/11 | 36.4 | 11.1 ± 1.2 | 0.022 | ||
| 1.0 | 12/12 | 100.0 | 16.0 ± 0 | <0.0001 | ||
| 10 | 11/11 | 100.0 | 16.0 ± 0 | <0.0001 | ||
| Oseltamivir | 0.01 | 5/11 | 45.5 | 12.2 ± 1.2 | 0.018 | |
| 0.1 | 4/11 | 36.4 | 11.9 ± 1.0 | 0.007 | ||
| 1.0 | 11/11 | 100.0 | 16.0 ± 0 | <0.0001 | ||
| 10 | 12/12 | 100.0 | 16.0 ± 0 | <0.0001 | ||
| PBS (control) | 0 | 0/11 | 0 | 8.0 ± 0.4 |
a
RWJ-270201 and oseltamivir were administered to BALB/c mice by twice-daily oral gavage for 5 days begining 4 h before viral infection. Control (infected untreated) animals received sterile PBS on the same schedule.
b
Mean survival time was estimated by the Kaplan-Meier method.
c
Differences in survival between the treatment and the control groups were analyzed by using the log-rank test.